Literature DB >> 23093267

Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients.

Benjamin Nisman1, Tanir Allweis, Luna Kadouri, Bela Mali, Tamar Hamburger, Mario Baras, Simon Gronowitz, Tamar Peretz.   

Abstract

BACKGROUND: We compared two recently developed immunoassays for serum thymidine kinase 1 (TK1) activity: one manual assay (DiviTum, Biovica(®)) and one fully automated assay (Liaison, Diasorin(®)).
METHODS: The study included 368 women: 149 healthy blood donors (control), 59 patients with benign breast disease (BBD) and 160 patients with primary breast cancer (BC).
RESULTS: A regression analysis of the Liaison (y) and DiviTum (x) assays for all three groups yielded the equation y=3.93+0.03x (r=0.85, n=368). The r-value in BC was higher than in control and BBD (0.90 vs. 0.81 and 0.64). The correlation between the two assays for TK1 values above the cut-off was higher compared to that below (0.88 and 0.59). Breakdown of the BBD group into subgroups with proliferative and non-proliferative lesions was effective only with the measurement of TK1 with DiviTum assay (p=0.03). The TK1 activity determined preoperatively in BC patients with DiviTum and Liaison assays was significantly associated with T-stage (for both p=0.01), presence of vascular invasion (p=0.002 and p=0.02), lack of estrogen receptor (ER) (p=0.001 and p=0.01) and progesterone receptor (PR) (p=0.01 and p=0.03) expression. Only TK1 analyzed with the DiviTum assay was associated with tumor grade and molecular subtype of BC (p=0.02 and p=0.003). Multivariate Cox proportional hazards analyses demonstrated that T-stage, PR status and TK1 activity measured by both methods (DiviTum, RR=3.0, p=0.02 and Liaison, RR=3.1, p=0.01) were independent predictors of disease recurrence.
CONCLUSIONS: In spite of differences observed between TK1 activity measured by the DiviTum and Liaison assays, both of them may be used for recurrence prediction in preoperative evaluation of BC patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23093267     DOI: 10.1515/cclm-2012-0162

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  12 in total

1.  Diagnostic and Prognostic Value of Serum Thymidine Kinase 1 in Cancer Patients.

Authors:  Yantao Li; Rongna Wei; Shilin Song
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-06       Impact factor: 0.900

Review 2.  A review of HPRT and its emerging role in cancer.

Authors:  Michelle H Townsend; Richard A Robison; Kim L O'Neill
Journal:  Med Oncol       Date:  2018-05-05       Impact factor: 3.064

3.  Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.

Authors:  M Bolayirli; C Papila; G G Korkmaz; B Papila; F Aydoğan; A Karataş; H Uzun
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

4.  Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.

Authors:  Kiran Kumar Jagarlamudi; Lars Olof Hansson; Staffan Eriksson
Journal:  BMC Cancer       Date:  2015-02-18       Impact factor: 4.430

5.  Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.

Authors:  Martina Bonechi; Francesca Galardi; Chiara Biagioni; Francesca De Luca; Mattias Bergqvist; Magnus Neumüller; Cristina Guarducci; Giulia Boccalini; Stefano Gabellini; Ilenia Migliaccio; Angelo Di Leo; Marta Pestrin; Luca Malorni
Journal:  Oncotarget       Date:  2018-03-27

6.  Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Authors:  Nusayba Bagegni; Shana Thomas; Ning Liu; Jingqin Luo; Jeremy Hoog; Donald W Northfelt; Matthew P Goetz; Andres Forero; Mattias Bergqvist; Jakob Karen; Magnus Neumüller; Edward M Suh; Zhanfang Guo; Kiran Vij; Souzan Sanati; Matthew Ellis; Cynthia X Ma
Journal:  Breast Cancer Res       Date:  2017-11-21       Impact factor: 6.466

Review 7.  Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.

Authors:  Amelia McCartney; Ilenia Migliaccio; Martina Bonechi; Chiara Biagioni; Dario Romagnoli; Francesca De Luca; Francesca Galardi; Emanuela Risi; Irene De Santo; Matteo Benelli; Luca Malorni; Angelo Di Leo
Journal:  Front Oncol       Date:  2019-07-23       Impact factor: 6.244

8.  Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer.

Authors:  Feiyu Chen; Lili Tang; Ting Xia; Ellen He; Guozhu Hu; Yuan Li; Ming Zhang; Ji Zhou; Staffan Eriksson; Sven Skog
Journal:  Mol Clin Oncol       Date:  2013-07-19

9.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

10.  A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.

Authors:  J Kiran Kumar; A C Aronsson; G Pilko; M Zupan; K Kumer; T Fabjan; J Osredkar; S Eriksson
Journal:  Tumour Biol       Date:  2016-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.